Ventyx Biosciences, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form 15 / Schedule TO; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$27M
Investors
1
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Ventyx Biosciences, Inc. is an entity organized in Delaware that first filed a Form D on March 15, 2021 and most recently amended it on March 16, 2026. The offering claims Securities Exchange Act of 1934. Ventyx Biosciences, Inc. reported $26,999,940 sold from 1 investor as of the Form D filed March 16, 2026. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. The issuer's address of record is 12790 El Camino Real, Suite 200, San Diego, CA 92130.
EDGAR Filing Data
Form 15 / Schedule TO — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
2
latest Mar 16, 2026
Critical / warning
0 / 1
1 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
3
closed, lapsed
Latest event Exchange act deregistration · Mar 16, 2026
SEC.govFund family Beneficially owned by MORGAN STANLEY · full family and the filing behind each link in the terminal
Investor
- The full fund family and 1 related vehicle (parallel, feeder, successor, sibling series) with the filing that shows each link
- 2 filing events with values and deltas, latest 2026-03-16, and alerts on the next one
- 3 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2024-09-30: 5 related persons added and 5 removed against the filing of 2021-09-20; 9 now listed. The names are in the Terminal feed.
Raju Mohan
Executive Officer, Director · San Diego, CA
John Nuss
Executive Officer · San Diego, CA
Somasundaram Subramaniam
Director · San Diego, CA
Matthew Moore
Executive Officer · San Diego, CA
Mark S. Forman
Executive Officer · San Diego, CA
Sheila S. Gujrathi
Director · San Diego, CA
Onaiza S. Cadoret-Manier
Director · San Diego, CA
Allison S. Hulme
Director · San Diego, CA
William S. White
Director · San Diego, CA
Questions About Ventyx Biosciences, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Ventyx Biosciences, Inc.?
Ventyx Biosciences, Inc. is an issuer that filed a Form D with the SEC on March 16, 2026. The filing claims Securities Exchange Act of 1934.
Is Ventyx Biosciences, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Ventyx Biosciences, Inc. filed a Form D with the SEC on March 16, 2026 claiming Securities Exchange Act of 1934. A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $26,999,940 sold to 1 investor. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Ventyx Biosciences, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Ventyx Biosciences, Inc. claimed Securities Exchange Act of 1934 and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Ventyx Biosciences, Inc. raised?
Ventyx Biosciences, Inc. reported $26,999,940 sold from 1 investor as of the Form D filed March 16, 2026.
Who is selling Ventyx Biosciences, Inc. and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.
Who is behind Ventyx Biosciences, Inc.?
The Form D lists 9 related persons: Raju Mohan, executive officer, director; John Nuss, executive officer; Somasundaram Subramaniam, director; Matthew Moore, executive officer; Mark S. Forman, executive officer; Sheila S. Gujrathi, director; Onaiza S. Cadoret-Manier, director; Allison S. Hulme, director, and 1 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Ventyx Biosciences, Inc. located?
The issuer's address on its SEC filings is 12790 El Camino Real, Suite 200, San Diego, CA 92130. Its phone number of record is 7604076511. It is organized under the laws of Delaware.
How long is the Ventyx Biosciences, Inc. offering open?
An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
